Tempus AI, Inc. has entered into a significant agreement with AstraZeneca AB, extending their collaboration and securing a financial commitment of $200 million over the next five years. This deal, effective January 1, 2027, is a major step for Tempus, as it reinforces its strategic position in the rapidly evolving field of computer programming and data processing.

The extension of the Master Services Agreement (MSA) between Tempus and AstraZeneca was filed on November 18, 2026. This agreement, originally established in November 2021, has now been renewed through December 31, 2031, with the potential for further extension under certain conditions.

According to the filing, AstraZeneca has committed to an aggregate of $200 million in fees to be paid to Tempus, which translates to an annual target spend of $40 million across existing and future products and services. The agreement also stipulates a minimum financial commitment of $32 million each year during the renewal term. If AstraZeneca does not meet this financial commitment by the end of the term, the agreement will automatically extend by one year to allow for the shortfall to be addressed.

AstraZeneca retains the right to terminate the MSA at any time. However, if the company has not fulfilled its financial commitments by the termination date, it will be liable to pay Tempus for any shortfall in the $200 million commitment.

Tempus AI, Inc. operates in the services sector, specifically in computer programming and data processing, as classified under SIC 7370. The firm has been making strides in leveraging artificial intelligence and multimodal data to enhance drug discovery and clinical development processes.

This agreement not only solidifies Tempus's financial outlook but also highlights the increasing reliance on data-driven solutions in the healthcare industry. As AI continues to transform various sectors, Tempus's collaboration with AstraZeneca positions it well among its competitors in the tech space.

Looking ahead, the filing does not specify any further immediate actions or upcoming filings related to this agreement, but the financial commitment from AstraZeneca is expected to bolster Tempus's operations significantly.